ACB:NYE-Aurora Cannabis Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NYE

Last Closing Price

USD 8.71

Change

0.00 (0.00)%

Market Cap

USD 1.59B

Volume

0.03B

Average Target Price

USD 11.26 (+29.23%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories, including valves, screens, etc.; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and ROAR Sports. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

N/A

USD76.13B 47.93 31.03
TAK Takeda Pharmaceutical Company ..

N/A

USD55.16B 102.71 0.13
CTLT Catalent, Inc

N/A

USD15.59B 59.16 25.63
ELAN Elanco Animal Health Incorpora..

N/A

USD15.00B 144.89 151.28
RDY Dr. Reddy's Laboratories Limit..

N/A

USD10.80B 51.53 0.33
TEVA Teva Pharmaceutical Industries..

N/A

USD10.55B 872.00 16.02
BHC Bausch Health Companies Inc

N/A

USD6.77B N/A 21.17
PRGO Perrigo Company plc

N/A

USD6.54B 24.33 13.97
EBS Emergent BioSolutions Inc

N/A

USD4.26B 26.49 13.06
TARO Taro Pharmaceutical Industries..

N/A

USD2.62B 10.60 4.58

ETFs Containing ACB

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

N/A

USD0.57B
THCX The Cannabis ETF 0.00 % 0.70 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 303.24% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 303.24% 100% A+ 99% A+
Trailing 12 Months  
Capital Gain 245.63% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 245.63% 100% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.75% N/A N/A 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.75% N/A N/A 11% F
Risk Return Profile  
Volatility (Standard Deviation) 48.70% N/A N/A 8% F
Risk Adjusted Return -17.96% N/A N/A 23% F
Market Capitalization 1.59B 44% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.16 86% B 95% A
Price/Book Ratio 0.80 100% A+ 80% B-
Price / Cash Flow Ratio -4.72 89% B+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -103.28% 17% F 3% F
Return on Invested Capital -88.05% 11% F 2% F
Return on Assets -6.71% 28% F 6% F
Debt to Equity Ratio 13.71% 80% B- 85% B
Technical Ratios  
Short Ratio 0.77 94% A 73% C
Short Percent N/A N/A N/A N/A N/A
Beta 1.59 18% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector